ACB
A green shoot, but not a full bloom
Aurora Cannabis turned in fiscal first-quarter 2027 net revenue of C$67.6 million, which is the kind of number that says, “Hey, there’s life here,” without exactly screaming victory lap.
The good news: international medical cannabis sales kept growing, giving the company a bit of lift. The less fun part: Canadian medical revenue fell after reimbursement changes, which is a reminder that even in cannabis, policy can be the real buzzkill.
What investors should watch
If you own ACB, the storyline is pretty simple: can Aurora lean more on international demand and less on a home market that keeps throwing up speed bumps?
A few things matter here:
- International medical growth is doing the heavy lifting
- Canadian reimbursement changes are pressuring revenue
- The mix shift matters, because not all revenue is created equal
Big picture
This is still a company trying to prove that its growth engine works beyond one market. If Aurora can keep building abroad while stabilizing the Canada business, the stock gets a lot more interesting. If not, it’s the same old cannabis plot twist: promising headlines, messy execution.